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Aims This communication describes the design of the FOLLOWPACE study. The overall aim of FOLLOW-
PACE is to quantify the cost-effectiveness of routine follow-up visits in patients with a pacemaker (PM).
Speciﬁc aims are (i) to quantify the incidence of complications and the quality of life 1 year after PM
implantation; (ii) to quantify which baseline characteristics measured during implantation are
predictors of the occurrence of complications and quality of life after 1 year; (iii) to determine
the added predictive value of follow-up measurements to improve the efﬁciency of follow-up and
to demonstrate which follow-up measurements are redundant.
Methods and results FOLLOWPACE is a prospective, observational, prognostic cohort study. About 40 PM
centres in the Netherlands will participate to include about 2500 patients. Each patient aged 18 receiv-
ing a PM for the ﬁrst time is eligible. At baseline, i.e. time of implantation, all potential predictors of
complications and quality of life after 1 year are documented. After implantation, follow-up visits will
be carried out conforming with routine care, usually three in the ﬁrst year. At these visits, other potential
prognostic predictors will be documented. Primary outcome is the incidence of PM- or cardiac compli-
cations at 1 year. Secondary outcome parameters are quality of life and costs after 1 year.
Conclusion This study will lead to deﬁnition of a more efﬁcient routine follow-up schedule for patients
with a PM, aiming to reduce time and energy while preserving the safety of pacing therapy and the
prognosis of the patient. The study will ultimately provide evidence-based guidelines for PM follow-up










In the Netherlands, approximately 5200 patients yearly
undergo a ﬁrst pacemaker (PM) implantation for AV block,
sinus node dysfunction, or other reasons.1,2 At present, it is
estimated that in the Netherlands, 70 000 patients have a
PM. In .70% of the ﬁrst implants, an atrioventricular
pacing system is implanted, and in the remainder, a right
ventricular system (25%) or pure atrial system (5%) is used.1,2
After PM implantation, two to three outpatient follow-up
visits are commonly carried out in the ﬁrst year and about
twice a year in subsequent years. For example, in the
Netherlands, about 150 000 PM follow-up visits are per-
formed yearly, yielding a total of 50 000 working hours.
During these visits, the physical condition of the patient is
checked as well as the technical function of the pacing
system, including battery status, pacing and sensing
parameters, and lead condition. Follow-up visits are com-
monly executed by a PM technician in co-operation with a
cardiologist, sometimes in combination with PM industry
personnel. The aim of the follow-up visits is to detect the
occurrence of potential complications at an appropriate
time, to optimize the condition of the patient and the PM,
and to prevent future complications and/or technical
failures of the pacing system.3–5
Complications may occur during or shortly (within days)
after the PM implantation as well as weeks to even years
after the implantation.6–8 The incidence of early compli-
cations (mostly deﬁned as within 6 weeks) varies from
0.5–11%.3,4,6–15 Implantation-related complications include
perforation of the vessels and cardiac chambers, infection
of the implanted system, lead displacement, and pocket
problems. The early complication rate after single-
chamber PM implantation appears to be ,2% and rates con-
sistently above these levels have been reported as a cause of
concern.6,8,9,12,13 Although one study did not ﬁnd differ-
ences in the incidence of early complications after the
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implantation of dual-chamber PMs compared with single-
chamber systems,9 most others showed and discussed that
the incidence of early complications was higher after dual-
chamber system implantation.4,8,10–12,14,15 This was said to
be due to complications associated with the atrial leads
with active ﬁxation properties and implantation of two
leads. In addition, the overall implantation time is signiﬁ-
cantly longer, which may predispose to wound infection.
Various studies have reported on the incidence of late(r)
complications after PM implantation.4,7,8,10,11,15–17 Recently,
a large study among 1000 PM patients in the United States
showed that, in a period of 7 years after implantation, the
frequency of complications (including inadequate capture
or sensing, PM pocket infection, and erosion) varied
between 4.5 and 15.9%.17
At present, data on the quality of life of PM patients and
the impact of follow-up measurements and visits on this
quality of life are lacking. Similarly, there is hardly any
quantitative evidence on which, patient and PM, character-
istics measured during implantation may predict the occur-
rence of short and long(er)-term complications and which
measurements at the routine follow-up visits indeed have
added predictive value. It is unknown whether all routine
PM follow-up visits are truly needed. It might be well that
some follow-up visits may not provide any additional prog-
nostic information and may, therefore, not be necessary in
terms of patient outcome. If so, reducing the routine
follow-up strategy by one or perhaps two visits would
reduce patient burden and costs without compromising
patient outcome.
Given the increase in number of PM implantations,1 the
limited ﬁgures on (longer term) complications and quality
of life after implantation and the absence of knowledge on
prognostic factors for these complications, we designed
the FOLLOWPACE study. In this article, we describe the
rationale, design, and implications of the results of this
large prospective prognostic study.
Design and analysis of the FOLLOWPACE study
Objectives
The FOLLOWPACE study is a prospective cohort study, per-
formed in 40 PM centres in the Netherlands. The overall
objective of the study is to quantify the cost-effectiveness
of routine follow-up visits in patients who receive a PM for
the ﬁrst time. This study will help to improve the quality
and efﬁciency of the initial PM implantation and follow-up
and to develop more evidence-based guidelines on the
responsibilities of different parties involved in the PM
follow-up.
Speciﬁc objectives are (i) to determine the incidence of
complications occurring in the ﬁrst year after implantation
of a PM; (ii) to determine the quality of life at 1 year
after PM implantation in comparison with the quality of
life before implantation; (iii) to determine which baseline
(patient and PM related) characteristics measured during
implantation are prognostic predictors for the occurrence
of complications and quality of life after 1 year; (iv) to
determine which characteristics measured during follow-
up visits have truly added predictive value and to what
extent; (v) to determine to what extent responsibilities for
PM check-up can safely be delegated to non-cardiologists
(e.g. PM technicians or manufacturers’ representatives).
Patients
Each patient aged 18 receiving a PM for the ﬁrst time in
one of the participating centres is a potential candidate
for the study. Patients are not eligible if they refuse to
sign informed consent. Patients who are taking any investi-
gational (new) drug or have a non-approved or investi-
gational PM system, which requires unusual follow-up, are
also excluded. In addition, patients having diseases that
are likely to cause death or signiﬁcant morbidity during
the study period, such as neoplasia and immune, infectious,
or degenerative diseases will be excluded.
Measurements
The moment of implantation is considered the baseline visit
of the present study. Before PM implantation, the patients
are asked to sign an informed consent and to ﬁll out a
systematic questionnaire on the quality of life, using the
standardized EuroQol and Aquarel questionnaires. Next,
information on patient characteristics is systematically
documented. The PM implantation takes place following
normal centre-speciﬁc routine. Information on the implan-
tation procedure and types of PM and leads are also system-
atically registered. All possible complications during the
implantation are documented.
Following implantation, the patient enters the regular
post-implantation follow-up. All visits after discharge are
considered as follow-up visits. These follow-up visits will
be performed according to the standard practice in each
participating centre. During follow-up visits, the health
status of the patient and the technical function of the
pacing system will be checked to investigate possible com-
plications in the patient and failures of the PM system. At
1 year, the last follow-up visit in this study is performed.
At this visit, the baseline questionnaires regarding quality
of life will be repeated.
Cardiologists and PM technicians of the participating
centres will perform the registration of the necessary data
at baseline and during follow-up, using an electronic case
record form (internet WebPages; www.followpace.nl).
At the implantation visit, each patient receives a diary in
which they can document all events, including medical or
paramedical consultations, treatments, and potential cardio-
vascular related complications, occurring during the study
period.
Prognostic predictors under study
The potential prognostic predictors of the various outcomes
(discussed subsequently) that are considered in this study
are placed in two categories: (i) predictors documented at
baseline (i.e. measured just before and during the PM
implantation) and (ii) predictors documented at the
follow-up visits.
Predictors recorded at baseline
The potential prognostic predictors recorded just before and
during the implantation are, in turn, categorized into three
groups as follows.
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(i) Patient characteristics such as age, sex, body mass index,
cardiovascular risk factors, medical history, and prescribed
medication.
(ii) Implantation-related characteristics such as indication
for pacing, duration of the implantation procedure, site
and type of vascular entrance, experience of the implanting
team, and contribution of persons supporting the implan-
tation procedure (e.g. PM technicians and PM manu-
facturers’ representatives).
(iii) PM- and lead-related characteristics such as type of PM
and leads, default values, pacing and sensing parameters,
pulse duration, output, sensitivity, measured lead resist-
ance, PM programming, and changes in default values. The
reason(s) why and by whom these changes are performed
and ordered are also recorded.
Predictors recorded at the follow-up visits
Following implantation, each patient will attend follow-up
visits in agreement with local routine practice. All data col-
lected at routine PM follow-up visits will be documented.
Potential predictors measured at each follow-up visit
include symptoms and signs of the patient, changes in
medication use, and results of diagnostic tests such as
Holter-monitoring, echocardiography, laboratory tests, and
X-rays. Furthermore, all changes made in PM programming
or default values, reasons for change as well as the




The primary outcome is the incidence of complications
within 1 year after implantation. During implantation as
well as at every follow-up visit, the presence of compli-
cations will be determined. These complications include
cardiac complications, traumatic complications (cardiac
perforation related), wound complications (such as haema-
tomas or infections), lead-related complications (pacing/
sensing problems), arrhythmias (newly developed during or
after implantation), non-cardiac muscle stimulation (dia-
phragmatic or pocket), non-PM-related complications, and
death (cardiac and non-cardiac).
Time of occurrence of the complication and duration of
the complication (if applicable), person responsible for
detecting the complication, and action undertaken as a
result of it will also be documented at each follow-up
visit. We will also study the diaries of the patients for rel-
evant data on complications, medical interventions, visits
to medical or paramedical services, medication changes,
and other factors potentially related to the occurrence of
complications.
Secondary outcome
Secondary outcomes include the quality of life after 1 year
and costs (to enable comparison of the cost-effectiveness
of the current follow-up process with the expected
cost-effectiveness of alternative follow-up strategies as
indicated by the results of the present study).
Quality of life will be measured using the standardized
EuroQol and Aquarel. These questionnaires contain general
and more disease-speciﬁc questions on physical and
mental health perception.18–21 Both questionnaires are
measured at baseline (before implantation) and at 1 year
after implantation. Changes in health perception can thus
be measured.
Costs are estimated in terms of actual cost prices (society
perspective). Medical consumption or volume of resource
use will be recorded. Actual costs per item, including the
follow-up visits with all necessary measurements, general
practice visits, medical specialist visits, cardiac (re)inter-
ventions, and hospitalization will be determined. Multiplying
average resource use with the pertaining prices will yield an
estimate of costs per individual PM patient. Where unavail-
able or insigniﬁcant in terms of volume or costs, tariffs may
be used as a proxy of the actual costs. To compare the cost-
effectiveness of the current follow-up strategy with that of
alternative follow-up strategies, see Data analysis.
Data analysis
First, the incidence of complications within 1 year with 95%
conﬁdence interval (Objective 1) and the difference in mean
quality of life at 1 year and at baseline (Objective 2) will be
estimated.
To quantify which baseline characteristics are predictors of
the occurrence of complications within 1 year (Objective 3)
and which follow-up measurements have truly added pre-
dictive value (Objective 4), stepwise multivariable logistic
regression analysis will be used. This stepwise analysis will
follow the chronological order in which measurements are
performed in daily practice. Hence, we ﬁrst estimate
which baseline predictors have independent prognostic
value and we quantify the predictive accuracy (using recei-
ver operating characteristic curves as well as calibration
curves22,23) of these predictors. Subsequently, we quantify
which predictors measured at the ﬁrst follow-up visit have
prognostic value additional to the baseline predictors,
using the same analytical approaches. Then, the incremen-
tal predictive value of the predictors measured at the
second and third follow-up visit will be estimated.
All these analyses will yield which baseline measurements
and which follow-up measurements are truly predictive and
thus necessary in terms of patient outcome. This, in turn,
provides an indication of who should perform and, thus,
who is responsible for these (follow-up) measurements
(Objective 5). This will lead to the deﬁnition of a more efﬁ-
cient strategy for follow-up of patients receiving a PM. We
also aim to deﬁne simple prognostic scores that can be
used by care providers to estimate a patient’s risk of devel-
oping a complication. These prognostic scores will be vali-
dated and adjusted for overoptimism using bootstrapping
techniques.23
Similarly, using stepwise multivariable linear (not logistic
as quality of life is a continuous outcome variable) regres-
sion analysis, we will also quantify which, combination of,
baseline characteristics are predictors for the patient’s
quality of life after 1 year and which follow-up measure-
ments have truly added predictive value.
To quantify the cost-effectiveness, the balance of esti-
mated costs and effects of various follow-up strategies,
including the current routine strategy and alternative strat-
egies with less measurements or visits as indicated by the
earlier described analysis, will be estimated and compared.
Overall costs will be directly compared, as well as overall
effects (expressed in terms of expected number of
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complications and QALYs). The ratio of these two para-
meters between two different follow-up strategies, i.e.
the incremental costs per additional complication, will be
reported using the following formula.
Costs alternative strategy  Costs current strategy
Effects alternative strategy  Effects current strategy
The follow-up strategy yielding the highest health effect
per unit of (monetary) input can thus be identiﬁed. Cost-
effectiveness will eventually be reported in terms of costs
per complication averted and costs per QALY gained.
Univariate and multivariate probabilistic sensitivity analysis
will be performed to assess uncertainty around the
incremental cost-effectiveness ratios. For long-term cost-
effectiveness analysis, and extrapolation, time preference
will be accounted for by a 4% discount rate.
Number of patients required
In clinical practice, estimating a patient’s prognosis is a
multivariable concern per se. No prognosis is set by one
single predictor. Physicians commonly consider various prog-
nostic factors together to estimate a patient’s probability of
developing a complication. To serve practice, scientiﬁc
prognostic studies must follow this multivariable process in
design and analysis. This, however, raises problems for the
estimation of the required number of patients for prognostic
studies. When the prognostic value of several predictors
together needs to be quantiﬁed, no straightforward
methods to estimate the required patient number, as exist
for therapeutic research, are yet available. A frequently
used ‘rule of thumb’ recommends that for each predictor
included in the analysis, at least 10 patients with an event
(i.e. with a complication) are necessary.23–25 This rule of
thumb is increasingly applied in prognostic studies. It is
expected that after pre-selection of predictors based on
clinical reasoning, about 20–30 predictors will be selected
for the analysis. Therefore, 200–300 patients with a compli-
cation are needed.
Prior research showed that 10–15% PM-related or
cardiac complications occur within 1 year. This means that
for the primary analysis, about 2500 patients with new
implanted PMs need to be included allowing for a sufﬁcient
number of events (about 250–375). Because the mean
number of PMs implanted in the Netherlands is about 70
PMs per centre per year, about 40 centres need to parti-
cipate in this study to include a sufﬁcient number of
patients.1,26
Implications of study results
Follow-up visits aim to determine the stability of the
patients health, to customize the PM programme to the
patient, and to further prevent the occurrence of cardiac
or PM-related complications. During these visits, numerous
data from the patient, the PM and the leads, are measured
and documented. Until now, no studies are available on how
important these measurements really are with respect to
patient outcomes. It may be well that some of these
measurements or even complete follow-up visits are redun-
dant and can thus be omitted from routine follow-up.
Hence, it is relevant to know which pacing and patient-
related characteristics are prognostically important, i.e.
have true predictive value for the occurrence of future
complications and quality of life. In previous studies using
quality of life as outcome in PM patients, quality of life
was measured with a generic instrument (SF 36), on the
basis of patient cohorts of a particular age (mainly
elderly), receiving a speciﬁc pace mode and with a limited
sample size.27–31 In the FOLLOWPACE study, quality of life
is not measured using the SF-36 but with the Aquarel ques-
tionnaire.20,21 Besides generic questions, this questionnaire
also contains questions on quality of life speciﬁcally desig-
ned for patients with a PM. Previous (validation) studies
have proven that Aquarel is both a feasible and a useful
tool in evaluating health perception of PM patients.20,21
Furthermore, the FOLLOWPACE study is a prospective
study across all ages, including all types of pacing modes,
and with a large sample size, guaranteeing sufﬁcient
representativeness and generalizability of the study results.
Finally, the FOLLOWPACE study will also provide know-
ledge on who should be involved in the PM follow-up visits
(e.g. cardiologist, PM technician, and industry personnel)
and to what extent. Eventually, this study will help to
improve quality and efﬁciency of implantation and follow-
up of patients with a PM.
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